Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ofloxacin and the treatment of pulmonary disease due to Mycobacterium fortuitum.

Literature DB >> 3479304

Ofloxacin and the treatment of pulmonary disease due to Mycobacterium fortuitum.

Abstract

A 58-year-old man with pulmonary disease due to Mycobacterium fortuitum was treated successfully with ofloxacin (0.3 g daily). Negative conversion of sputum culture was achieved immediately after administration of ofloxacin, and the chest roentgenogram also improved.

Entities: Chemical Disease Species

Mesh：

Substances：
Oxazines
Ofloxacin

Year: 1987 PMID： 3479304 DOI： 10.1378/chest.92.6.1110

Source DB: PubMed Journal: Chest ISSN： 0012-3692 Impact factor: 9.410

Keyword Cloud
Cited

7 in total

1. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.

Authors:
Journal: Thorax Date: 2000-03 Impact factor: 9.139

Review 2. Mycobacteria and the new quinolones.

Authors: D C Leysen; A Haemers; S R Pattyn
Journal: Antimicrob Agents Chemother Date: 1989-01 Impact factor: 5.191

3. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy.

Authors: R J Wallace; G Bedsole; G Sumter; C V Sanders; L C Steele; B A Brown; J Smith; D R Graham
Journal: Antimicrob Agents Chemother Date: 1990-01 Impact factor: 5.191

Ofloxacin and the treatment of pulmonary disease due to Mycobacterium fortuitum.

1. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.

Review 2. Mycobacteria and the new quinolones.

3. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy.

4. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a.

5. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.

Review 6. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria.

Review 7. Fluoroquinolone antimicrobial agents.